{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:10:13Z","timestamp":1790644213472,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ijantimicag.2018.11.015","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T10:43:20Z","timestamp":1542883400000},"page":"520-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam"],"prefix":"10.1016","volume":"53","author":[{"given":"Cristina","family":"De la Calle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-0055","authenticated-orcid":false,"given":"Olga","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1863-6379","authenticated-orcid":false,"given":"Francesc","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garc\u00eda-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Del","family":"R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Feher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pellic\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Puerta-Alcalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijantimicag.2018.11.015_bib0001","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijantimicag.2018.11.015_bib0002","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.11.015_bib0003","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.ijantimicag.2018.11.015_bib0004","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ijantimicag.2018.11.015_bib0005","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.ijantimicag.2018.11.015_bib0006","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, RECAPTURE, a Phase 3 Randomized Trial Program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.11.015_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijantimicag.2018.11.015_bib0008","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ijantimicag.2018.11.015_bib0009","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.015_bib0011","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jac\/45.4.467","article-title":"Molecular epidemiology of an outbreak due to IRT-2 \u03b2-lactamase-producing strains of Klebsiella pneumoniae in a geriatric department","volume":"45","author":"Girlich","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.015_bib0012","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1128\/JCM.43.8.4178-4182.2005","article-title":"Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates","volume":"43","author":"Diancourt","year":"2005","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.ijantimicag.2018.11.015_bib0013","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.ijantimicag.2018.11.015_bib0014","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2018.11.015_bib0015","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijantimicag.2018.11.015_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.ijantimicag.2018.11.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.015_bib0018","article-title":"Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae","author":"van Duin","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.ijantimicag.2018.11.015_bib0019","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/1469-0691.12697","article-title":"Treating infections caused by carbapenemase-producing Enterobacteriaceae","volume":"20","author":"Tzouvelekis","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.ijantimicag.2018.11.015_bib0020","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T19:27:36Z","timestamp":1605468456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0924857918303406"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.015","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}